CCR2 and Kaposi's sarcoma: Savino et al. found that combined targeting of CCR2 and the ERK pathway might provide a promising therapeutic strategy for the treatment of Kaposi sarcoma, where these treatments involve the inhibition of angiogenesis and subsequent tumor growth.